Therakos Institute Partnerships

NEW Partnership with the SOT Hub – Platinum Sponsors in 2026

Therakos is pleased to be a platinum sponsor and founding partner of the Solid Organ Transplantation Hub (SOT Hub), an independent, digital platform designed to support education and knowledge-sharing in the field of solid organ transplantation.

VISIT THE SOTHub

Strategic Initiatives

The SOT Hub brings together scientific content developed independently by SES, in collaboration with an expert steering committee. Therakos has no influence over the editorial content of the platform.

Through this partnership, Therakos supports the SOT Hub's mission to foster collaboration, discussion, and access to high-quality information for healthcare professionals involved in solid organ transplantation.

Therakos–GETH Educational Partnership 2026

Therakos is pleased to announce its educational partnership with the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH) throughout 2026.

Strategic Initiatives

As part of this collaboration, GETH will deliver two accredited medical education webinars focused on advancing clinical practice in Graft-versus-Host Disease (GvHD). Topics will include the early use of ECP in combination with ruxolitinib for aGVHD, its impact on cGvHD incidence, and real-world European and Spanish experience, as well as the role of ECP in early treatment lines and its effect on patient quality of life.

Each webinar will be followed by expert-led clinical case discussions, offering practical insights from key opinion leaders. GETH will support the initiative through a dedicated communication campaign and on-demand access for its members.

Therakos looks forward to continuing this collaboration with GETH, fostering scientific exchange and contributing to improved patient outcomes through high-quality education.

GvHD Hub - Platinum Sponsors for 2026

GvHD Hub offers a unique platform for independent, up-to-date medical education and resources on GvHD. Therakos are proud to partner with them in 2026 as platinum sponsors.

The latest ECP related articles produced independently by the GvHD Hub can be accessed below.

VISIT THE GVHD HUB

Enhanced Partnership with GITMO

We are thrilled to announce the elevation of our partnership with GITMO, a cornerstone in the Bone Marrow Transplantation field. This collaboration not only elevates our reputation but also expands the clinical insights into the utilisation of Therakos ECP Immunomodulation in the GvHD treatment algorithm.

We are confident that this reinforced partnership with GITMO will drive advancements in Bone Marrow Transplantation and further our mission to serve the medical and patients' communities.

Key Highlights:

Webinar Collaboration: We are supporting a webinar facilitated by GITMO that will focus on "Therakos ECP Immunomodulation in Combinational Therapy Approaches in GvHD Treatment."

Patient Case Discussion Platform: We are introducing a dedicated platform for discussions of patient cases. This initiative, led by a committee of GITMO experts, invites participation from all Italian hospitals and GITMO members.

Educational Endeavors: GITMO has graciously agreed to promote Mallinckrodt's educational activities, ensuring that our valuable insights reach the broader medical community.

Strategic partners with ESOT

Our collaboration with ESOT (European Society of Solid Organ Transplantation), underscores our mutual commitment to advancing scientific knowledge and education in the realm of Solid Organ Transplantation (SOT).

Key Objectives: Foster discussions centered on the latest scientific advancements and therapeutic strategies, with a particular focus on Therakos ECP immunomodulation.

Visit the ESOT ECP Platform

Don’t forget to follow us for the latest on our events. More dates will be added soon, and throughout the year.

You can read more about our educational initiatives on our Therakos Institute page.

Updated Feb 2026 TKS-26-00119

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Therakos Institute Partnerships

NEW Partnership with the SOT Hub – Platinum Sponsors in 2026

Strategic Initiatives

Therakos–GETH Educational Partnership 2026

Strategic Initiatives

GvHD Hub - Platinum Sponsors for 2026

Enhanced Partnership with GITMO

Key Highlights:

Strategic partners with ESOT

Don’t forget to follow us for the latest on our events. More dates will be added soon, and throughout the year.

You can read more about our educational initiatives on our Therakos Institute page.

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS